Heartflow (NASDAQ:HTFL) Upgraded at Freedom Capital

Heartflow (NASDAQ:HTFL) was upgraded by Freedom Capital to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

HTFL has been the subject of a number of other reports. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. JPMorgan Chase & Co. lowered their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, March 19th. Wells Fargo & Company upped their price target on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. William Blair assumed coverage on shares of Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating on the stock. Finally, Piper Sandler reissued an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.00.

Heartflow Stock Down 8.9%

Shares of Heartflow stock opened at $27.97 on Tuesday. The business has a 50 day moving average of $30.66 and a 200 day moving average of $28.69. Heartflow has a 52 week low of $20.13 and a 52 week high of $41.22. The company has a market cap of $2.41 billion and a PE ratio of -8.99.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million during the quarter. The business’s revenue was up 41.3% compared to the same quarter last year. On average, research analysts anticipate that Heartflow will post -0.82 earnings per share for the current year.

Insider Activity

In related news, insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the completion of the transaction, the insider directly owned 78,731 shares in the company, valued at approximately $2,231,236.54. This trade represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total transaction of $27,732,167.11. Following the transaction, the insider owned 8,448,158 shares of the company’s stock, valued at $246,939,658.34. This trade represents a 10.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,115,805 shares of company stock worth $62,422,505 over the last three months. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Heartflow

Several large investors have recently bought and sold shares of HTFL. Fred Alger Management LLC acquired a new stake in shares of Heartflow in the 3rd quarter valued at about $9,997,000. Atika Capital Management LLC acquired a new position in Heartflow during the third quarter worth approximately $2,323,000. JPMorgan Chase & Co. purchased a new stake in Heartflow in the third quarter valued at approximately $13,887,000. Capital International Investors acquired a new stake in shares of Heartflow in the third quarter valued at approximately $43,671,000. Finally, Bamco Inc. NY acquired a new stake in shares of Heartflow in the third quarter valued at approximately $41,654,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.